[Bisphosphonates (BP) and osteonecrosis of the jaws; should administration of BP be discontinued at the early phase?].
Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine.
Masahiro
M
Urade
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates